Skip to content
View Damitri411's full-sized avatar
☀️
Focusing
☀️
Focusing

Block or report Damitri411

Block user

Prevent this user from interacting with your repositories and sending you notifications. Learn more about blocking users.

You must be logged in to block users.

Content in all repositories owned by your account will be closed.
Maximum 250 characters. Please don’t include any personal information such as legal names or email addresses. Markdown is supported. This note will only be visible to you.
Report abuse

Contact GitHub support about this user’s behavior. Learn more about reporting abuse.

Report abuse
Damitri411/README.md

Hi, I'm Damitri 👋

I build Bayesian statistical methods and tools for early-phase oncology trials — from dose-finding designs to PK/PD-informed dose optimisation to cure-rate survival models.

Most of my work is hands-on: R and JAGS/NIMBLE implementations, simulation studies, Shiny apps, and manuscripts translating theory into methods trial teams can actually use.

🧬 What I work on

  • Bayesian dose-finding & dose-optimisation — seamless Phase I/II frameworks combining PK/PD modelling with toxicity/efficacy dose-finding
  • Multi-agent combination designs — comparing designs (BOIN12, EffTox, COMIC, uTPI-Comb) for two-agent optimal biological dose identification
  • Cure-rate & survival modelling — mixture cure models for long-term outcome trials with non-susceptible fractions
  • Rare-disease trial methodology — restricted mean duration of response under non-proportional hazards, small-sample group-sequential designs
  • JAGS ↔ NIMBLE model porting, prior elicitation from published trial data, and simulation-based operating characteristics

📌 Pinned

  • PREDOSE — seamless Phase I/II Bayesian PK/PD dose-optimisation framework for oncology step-up dosing (manuscript targeting JASA)
  • OBDC-Compare-App — Shiny app comparing four Bayesian dose-finding designs for two-agent combination trials
  • PKComb-BOIN12 Simulator — Shiny app supporting PKComb-BOIN12: A Pharmacokinetics-Informed Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials (manuscript in preparation)
  • Estimands-for-Cure-Rate-Model — estimand and causal framework for cardiovascular trials with non-susceptible fractions

🧑‍🔬 About Me

  • Associate Advisor – Statistics, Early Phase Oncology Biostatistics @ Eli Lilly and Company; trial statistician on early-phase oncology studies including an ADC program
  • PhD in Statistics, Indian Statistical Institute, Kolkata — Bayesian joint modelling of multivariate longitudinal and time-to-event data
  • Full member, PSI (Statisticians in the Pharmaceutical Industry)
  • Published in Journal of Applied Statistics, Lifetime Data Analysis, and Journal of Biopharmaceutical Statistics
  • Previously a data scientist at RedBus and Intuit before moving into biostatistics
  • Core tools: R, JAGS, NIMBLE

📫 LinkedIn · Google Scholar · ResearchGate

Pinned Loading

  1. Damitri411 Damitri411 Public

    Biostatistician and Researcher focusing on: Early Phase Oncology Dose Optimization, Rare Diseases, Time to Event Data, Longitudinal Data, Bayesian Variable Selection, Multivariate Joint Modeling

    1